Recruiting
Phase 1

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Sponsor:

Cambridge Antibody Technology

Code:

NCT00457860

Conditions

Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Immunotoxin therapy

CAT-8015 immunotoxin

Biological therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information